Echolucent implants

Patent metadata

Field	Value
Publication number	US-2020206367-A1
Application number	US-202016817307-A
Country	US
Kind code	A1
Filing date	Mar 12, 2020
Priority date	Dec 15, 2009
Publication date	Jul 2, 2020
Grant date	—

Abstract

Echolucent implantable compositions are described. Applications include materials for delivering of therapeutic agents to a tissue at a placement site.

First claim

1 . A pharmaceutically acceptable implant composition comprising:
a hydrogel precursor composition, a therapeutic agent, and a pharmaceutically acceptable fluid, wherein the hydrogel precursor composition comprises a first precursor compound with a plurality of first functional groups and a second precursor compound with a plurality of second functional groups, wherein the first functional groups are capable of forming covalent bonds with the second functional groups at physiological conditions, and wherein the pharmaceutically acceptable implant composition is echolucent following reaction of the hydrogel precursor composition to form a collection of covalently-cross-linked, hydrolytically biodegradable hydrogel particles.

2 . The pharmaceutically acceptable implant composition of claim 1 further comprising a radiopaque agent.

3 . The pharmaceutically acceptable implant composition of claim 2 wherein the radiopaque agent is covalently attached to the hydrogel precursor composition.

4 . The pharmaceutically acceptable implant composition of claim 1 wherein the collection comprises hydrogel particles having an average diameter from about 10 microns to about 500 microns.

5 . The pharmaceutically acceptable implant composition of claim 1 wherein the collection comprises hydrogel particles having an average diameter from about 125 microns to about 500 microns.

6 . The pharmaceutically acceptable implant composition of claim 1 further comprising an ultrasound contrast agent.

7 . The pharmaceutically acceptable implant composition of claim 1 wherein the therapeutic agent comprises an anesthetic, a steroid, a chemotherapeutic agent, or combinations thereof.

8 . The pharmaceutically acceptable implant composition of claim 1 wherein a volume of the pharmaceutically acceptable implant composition increases no more than 50% in an in vitro physiological saline solution or an in vivo environment in a tissue.

9 . The pharmaceutically acceptable implant composition of claim 1 wherein the collection has a time for complete degradation from about 7 days to about 180 days in an in vivo environment in a tissue.

10 . The pharmaceutically acceptable implant composition of claim 1 wherein the collection is hydrolytically biodegradable in vivo to produce degradation products that are absorbed into the circulatory system and cleared from the body via renal filtration.

11 . The pharmaceutically acceptable implant composition of claim 11 wherein the degradation products of the hydrogel particles in the collection comprise a polyethylene glycol covalently bound to a radioopaque agent, wherein the radioopaque agent comprises iodine.

12 . The pharmaceutically acceptable implant composition of claim 1 wherein the pharmaceutically acceptable implant composition is a slurry or liquid that is deliverable through an applicator.

13 . The pharmaceutically acceptable implant composition of claim 1 further comprises an osmotic agent wherein the osmotic agent comprises a linear hydrophilic polymer.

14 . The pharmaceutically acceptable implant composition of claim 1 wherein the osmotic agent comprises polyethylene glycol.

15 . The pharmaceutically acceptable implant composition of claim 1 wherein the pharmaceutically acceptable implant composition is deliverable to a tissue at a placement site through an applicator, and wherein the applicator comprises a syringe, a catheter, a needle, a cannula, a hollow wire, or combinations thereof.

16 . The pharmaceutically acceptable implant composition of claim 15 wherein the pharmaceutically acceptable implant composition is adherent to the tissue.

17 . The pharmaceutically acceptable implant composition of claim 1 wherein the first or the second precursor compound comprises a polyethylene glycol.

18 . The pharmaceutically acceptable implant composition of claim 1 wherein the first or the second precursor compound comprises a branched polyethylene glycol having a plurality of arms.

19 . The pharmaceutically acceptable implant composition of claim 1 wherein the hydrogel particles and/or the pharmaceutically acceptable fluid comprise the therapeutic agent.

20 . The pharmaceutically acceptable implant composition of claim 1 wherein the therapeutic agent further comprises a surfactant, a lipid, a polyethylene glycol, a distinct release rate modifying agent, or a combination thereof.

Assignees

• Incept Llc

Inventors

• Campbell Patrick
• Sawhney Amarpreet S

Classifications

• A61L27/50 Primary

  Materials characterised by their function or physical properties {, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials} · CPC title

• A61L31/148

  Materials at least partially resorbable by the body · CPC title

• A61L31/145

  Hydrogels or hydrocolloids · CPC title

• A61K2123/00

  Preparations for testing in vivo · CPC title

• A61L27/58

  Materials at least partially resorbable by the body · CPC title